FinscoFinsco

Cytek Biosciences (US.CTKB)

Capital Allocation Audit · Period: 2019 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CTKB · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion424.7%↓
ROE-9.6%↓
Cash Conversion-→
D/E Ratio0.08↓
Gross Margin53.7%↑
US.CTKB (Cytek Biosciences) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   424.7%    ↓
ROE               -9.6%    ↓
Cash Conversion       -    →
D/E Ratio          0.08    ↓
Gross Margin      53.7%    ↑
Key Metrics
US.CTKB (Cytek Biosciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 424.7% ↓
ROE -9.6% ↓
Cash Conversion - →
D/E Ratio 0.08 ↓
Gross Margin 53.7% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies